Odanacatib
Odanacatib
Odanacatib (pronunciation: oh-dan-uh-KAT-ib) is a selective inhibitor of cathepsin K, an enzyme involved in the breakdown of bone in the body. It was developed by Merck & Co. for the treatment of osteoporosis and bone metastases.
Etymology
The name "Odanacatib" is derived from the combination of "Odan" and "catib", which are abbreviations for the terms "Odanacatib" and "cathepsin inhibitor" respectively. The exact origin of the term "Odan" is unknown.
Usage
Odanacatib is used in the treatment of osteoporosis, a condition that weakens bones and makes them prone to fractures. It works by inhibiting the activity of cathepsin K, an enzyme that plays a crucial role in the breakdown of bone. By inhibiting this enzyme, Odanacatib helps to maintain bone density and strength.
Related Terms
- Cathepsin K: An enzyme that breaks down proteins in the bone. Inhibition of this enzyme is the primary mechanism of action of Odanacatib.
- Osteoporosis: A medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of calcium or vitamin D.
- Bone metastases: The spread of cancer cells from their original site to bone.
- Merck & Co.: An American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. It is the developer of Odanacatib.
External links
- Medical encyclopedia article on Odanacatib
- Wikipedia's article - Odanacatib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski